Furthermore, DNA-PKcs inhibition (KU57788 and IC87361) has shown success in radiosensitising hypoxic (0.2% oxygen) HNSCC cell lines [86] and additionally SN38023, which is a hypoxia activated prodrug which releases the DNA-PKcs inhibitor IC87361 preferentially in hypoxic cells, was demonstrated to selectively radiosensitise anoxic UT-SCC54 cells [87]. The gene discussed is PRKDC; the disease is head and neck squamous cell carcinoma.